Key Takeaways
- • Ironleaf is backing HCS, a healthcare IT company, citing a fragmented healthcare IT market as the investment rationale, according to PE Hub Wire.
- • HIG and General Catalyst are reported to be targeting the hematology segment, per the headline of the story.
- • Astorg partner Olivier Lieven is featured in the "They Said It" section of the coverage.
Summary
PE Hub Wire reports that Ironleaf has decided to back HCS, with the fragmented structure of the healthcare information technology market cited as a key driver of the move. The story is framed around the broader healthcare IT opportunity rather than a detailed deal breakdown, and the available source text does not disclose transaction terms, valuation or investment size.
The headline also points to HIG and General Catalyst targeting hematology, indicating interest from both firms in that clinical specialty. The available coverage does not provide further detail on the scope of their strategies or any specific transactions in the segment.
The article includes a commentary feature in which Astorg partner Olivier Lieven contributes to the "They Said It" section. Coverage of the same story also appeared in PEI Private Equity, which carried the same headline, indicating the item is being reported across private equity trade publications.
The headline also points to HIG and General Catalyst targeting hematology, indicating interest from both firms in that clinical specialty. The available coverage does not provide further detail on the scope of their strategies or any specific transactions in the segment.
The article includes a commentary feature in which Astorg partner Olivier Lieven contributes to the "They Said It" section. Coverage of the same story also appeared in PEI Private Equity, which carried the same headline, indicating the item is being reported across private equity trade publications.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.